Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
Adagene Inc. (Nasdaq: ADAG) has appointed Dr. John Maraganore as Executive Advisor to mentor the C-suite and provide strategic guidance. Dr. Maraganore, former CEO of Alnylam (2002-2021), brings extensive experience in developing breakthrough therapeutics and creating substantial market value.
The appointment aligns with Adagene's focus on their proprietary masking technology for checkpoint inhibitors, specifically ADG126, which aims to deliver anti-CTLA-4 therapy selectively to tumor cells while minimizing toxicity. During his tenure at Alnylam, Dr. Maraganore led the company through global approvals of four RNA interference medicines and formed over 20 major pharmaceutical alliances, building over $25 billion in market capitalization.
Adagene Inc. (Nasdaq: ADAG) ha nominato Dr. John Maraganore come Consigliere Esecutivo per guidare il team dirigenziale e offrire consulenza strategica. Il Dr. Maraganore, ex CEO di Alnylam (2002-2021), porta con sé una vasta esperienza nello sviluppo di terapie innovative e nella creazione di un significativo valore di mercato.
La nomina è in linea con l'attenzione di Adagene sulla loro tecnologia proprietaria di mascheramento per gli inibitori del checkpoint, in particolare ADG126, che mira a somministrare la terapia anti-CTLA-4 in modo selettivo alle cellule tumorali riducendo al minimo la tossicità. Durante il suo mandato in Alnylam, il Dr. Maraganore ha guidato l'azienda all'approvazione globale di quattro farmaci basati sull'interferenza dell'RNA e ha stretto oltre 20 importanti alleanze con aziende farmaceutiche, contribuendo a un valore di mercato superiore a 25 miliardi di dollari.
Adagene Inc. (Nasdaq: ADAG) ha nombrado a Dr. John Maraganore como Asesor Ejecutivo para mentorizar al equipo directivo y brindar orientación estratégica. El Dr. Maraganore, ex CEO de Alnylam (2002-2021), aporta una amplia experiencia en el desarrollo de terapias innovadoras y en la creación de un valor de mercado significativo.
El nombramiento se alinea con el enfoque de Adagene en su tecnología patentada de enmascaramiento para inhibidores de puntos de control, específicamente ADG126, que busca administrar la terapia anti-CTLA-4 de manera selectiva a las células tumorales minimizando la toxicidad. Durante su gestión en Alnylam, el Dr. Maraganore lideró la aprobación global de cuatro medicamentos basados en interferencia de ARN y estableció más de 20 alianzas importantes con compañías farmacéuticas, construyendo una capitalización de mercado superior a 25 mil millones de dólares.
Adagene Inc. (나스닥: ADAG)는 Dr. John Maraganore를 임원 고문으로 임명하여 경영진을 멘토링하고 전략적 지침을 제공하도록 했습니다. Dr. Maraganore는 Alnylam의 전 CEO(2002-2021)로서 혁신적인 치료법 개발과 막대한 시장 가치를 창출한 풍부한 경험을 가지고 있습니다.
이번 임명은 Adagene가 독자적인 마스킹 기술을 적용한 체크포인트 억제제, 특히 ADG126에 집중하는 전략과 일치하며, 이는 종양 세포에 선택적으로 항-CTLA-4 치료를 전달하면서 독성을 최소화하는 것을 목표로 합니다. Alnylam 재임 기간 동안 Dr. Maraganore는 네 가지 RNA 간섭 약물의 전 세계 승인과 20건 이상의 주요 제약사 제휴를 이끌어 250억 달러 이상의 시장 가치를 구축했습니다.
Adagene Inc. (Nasdaq : ADAG) a nommé Dr. John Maraganore en tant que conseiller exécutif pour encadrer l'équipe dirigeante et fournir des conseils stratégiques. Dr. Maraganore, ancien PDG d'Alnylam (2002-2021), apporte une vaste expérience dans le développement de thérapies innovantes et la création d'une valeur de marché significative.
Cette nomination s'inscrit dans l'orientation d'Adagene vers leur technologie propriétaire de masquage pour les inhibiteurs de points de contrôle, en particulier ADG126, qui vise à administrer la thérapie anti-CTLA-4 de manière sélective aux cellules tumorales tout en minimisant la toxicité. Pendant son mandat chez Alnylam, Dr. Maraganore a conduit l'entreprise à l'approbation mondiale de quatre médicaments basés sur l'interférence ARN et a formé plus de 20 alliances majeures avec des sociétés pharmaceutiques, générant une capitalisation boursière de plus de 25 milliards de dollars.
Adagene Inc. (Nasdaq: ADAG) hat Dr. John Maraganore zum Executive Advisor ernannt, um das Führungsteam zu betreuen und strategische Beratung zu bieten. Dr. Maraganore, ehemaliger CEO von Alnylam (2002-2021), bringt umfassende Erfahrung in der Entwicklung bahnbrechender Therapeutika und der Schaffung erheblicher Marktwerte mit.
Die Ernennung steht im Einklang mit Adagenes Fokus auf ihre proprietäre Maskierungstechnologie für Checkpoint-Inhibitoren, insbesondere ADG126, das darauf abzielt, die Anti-CTLA-4-Therapie selektiv an Tumorzellen zu liefern und gleichzeitig die Toxizität zu minimieren. Während seiner Zeit bei Alnylam führte Dr. Maraganore das Unternehmen durch globale Zulassungen von vier RNA-Interferenz-Medikamenten und schloss über 20 bedeutende Partnerschaften mit Pharmaunternehmen ab, wodurch eine Marktkapitalisierung von über 25 Milliarden US-Dollar aufgebaut wurde.
- Appointment of highly experienced executive advisor with proven track record in drug development and commercialization
- Strategic alignment with advisor who successfully solved similar drug delivery challenges
- Access to extensive pharmaceutical industry network through advisor's connections with major venture firms and financial institutions
- None.
- Biotech luminary to mentor C-suite and provide strategic guidance -
SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor.
“Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibody drug conjugates,” said Dr. Maraganore. “I look forward to guiding and contributing to the Company’s growth, value creation and benefit for patients.”
Peter Luo, Ph.D., Cofounder, CEO and President of R&D at Adagene added, “John Maraganore’s legacy of solving the RNAi delivery challenge - once thought impossible - always inspires me. He and his team accomplished delivery of RNAi therapeutics to specific tissue cells in the human body without degradation and off-target toxicity. And this is exactly what we are doing with ADG126: delivering anti-CTLA-4 safely to specific T cells, minimizing off-tumor toxicity, and remaining inactive during circulation until ADG126 reaches the tumor. Although the modality is different, the problem we aim to solve is the same, and having John’s guidance is a tremendous opportunity for Adagene and our mission.”
Dr. John Maraganore was CEO of Alnylam from 2002 to 2021, where he led the Company through global approvals and commercialization of four RNA interference therapeutic medicines. While at Alnylam, Dr. Maraganore also led value creation efforts, forming over 20 major pharmaceutical alliances and building over
As a partner or advisor with ARCH Venture Partners, Atlas Ventures, Blackstone Life Sciences, Jefferies Financial Services, and RTW Investments, Dr. Maraganore also sits on public and private company Boards of Directors and actively advises and mentors life sciences CEOs.
Dr. Maraganore received his B.A., M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
raymond_tam@adagene.com
Bruce Mackle
LifeSci Advisors
bmackle@lifesciadvisors.com
FAQ
What is the significance of Dr. John Maraganore joining Adagene (ADAG) as Executive Advisor?
How does Adagene's (ADAG) ADG126 technology work in cancer treatment?
What were Dr. Maraganore's key achievements at Alnylam before joining Adagene (ADAG)?
What is the main focus of Adagene's (ADAG) current therapeutic development?
